A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Inclusion Criteria:

• Body weight ≥ 25 kilograms (kg)

• Diagnosis of RRMS in accordance with the International Pediatric Multiple SclerosisStudy Group (IPMSSG) criteria for pediatric Multiple Sclerosis (MS), Version 2012,or McDonald criteria 2017

• Expanded Disability Status Scale (EDSS) at screening: 0-5.5, inclusive

• For all countries except Germany, at least one MS relapse during the previous yearor two MS relapses in the previous 2 years or evidence of at least one Gd enhancinglesion on MRI within 6 months

Inclusion Criteria for Optional OLE Period:

-Participants in Group A (ocrelizumab in the double-blind period [DBP]) and Group B (fingolimod in the DBP) who, in the opinion of the investigator, may benefit from switching to ocrelizumab and who have completed the DBP with study treatment (ocrelizumab/fingolimod), may participate in the OLE period

Exclusion Criteria:

• Known presence or suspicion of other neurologic disorders that may mimic MS

• Significant uncontrolled somatic diseases, known active infection or any othersignificant condition that may preclude participant from participating in the study

• Participants with severe cardiac disease or significant findings on the screeningElectrocardiograph (ECG)

Exclusion Criteria for Optional OLE Period:

-Participants who have discontinued the study during the DBP